NL2023863B1 - Protein particles and uses thereof - Google Patents

Protein particles and uses thereof Download PDF

Info

Publication number
NL2023863B1
NL2023863B1 NL2023863A NL2023863A NL2023863B1 NL 2023863 B1 NL2023863 B1 NL 2023863B1 NL 2023863 A NL2023863 A NL 2023863A NL 2023863 A NL2023863 A NL 2023863A NL 2023863 B1 NL2023863 B1 NL 2023863B1
Authority
NL
Netherlands
Prior art keywords
protein
amino acid
acid sequence
crm
particle
Prior art date
Application number
NL2023863A
Other languages
English (en)
Dutch (nl)
Inventor
Helmut Adam Rehm Bernd
Chen Shuxiong
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Griffith filed Critical Univ Griffith
Priority to NL2023863A priority Critical patent/NL2023863B1/en
Priority to CN202080080056.6A priority patent/CN115175696A/zh
Priority to JP2022517738A priority patent/JP2022549791A/ja
Priority to EP20866415.1A priority patent/EP4031170A4/en
Priority to US17/761,744 priority patent/US20220378894A1/en
Priority to PCT/AU2020/000107 priority patent/WO2021051153A1/en
Priority to AU2020349589A priority patent/AU2020349589A1/en
Application granted granted Critical
Publication of NL2023863B1 publication Critical patent/NL2023863B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0208Specific bacteria not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL2023863A 2019-09-20 2019-09-20 Protein particles and uses thereof NL2023863B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof
CN202080080056.6A CN115175696A (zh) 2019-09-20 2020-09-21 包含白喉毒素交叉反应物质(crm)氨基酸序列的蛋白颗粒及其用途
JP2022517738A JP2022549791A (ja) 2019-09-20 2020-09-21 ジフテリア毒素交差反応物質(crm)アミノ酸配列を含むタンパク質粒子及びその使用
EP20866415.1A EP4031170A4 (en) 2019-09-20 2020-09-21 PROTEIN PARTICLES COMPRISING AN AMINO ACID SEQUENCE OF CROSS-REACTING DIPHTHERIETOXIN (CRM) AND USES THEREOF
US17/761,744 US20220378894A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
PCT/AU2020/000107 WO2021051153A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
AU2020349589A AU2020349589A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin Cross Reacting Material (CRM) amino acid sequence and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof

Publications (1)

Publication Number Publication Date
NL2023863B1 true NL2023863B1 (en) 2021-05-25

Family

ID=68425230

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof

Country Status (7)

Country Link
US (1) US20220378894A1 (https=)
EP (1) EP4031170A4 (https=)
JP (1) JP2022549791A (https=)
CN (1) CN115175696A (https=)
AU (1) AU2020349589A1 (https=)
NL (1) NL2023863B1 (https=)
WO (1) WO2021051153A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078177B (zh) * 2018-08-09 2022-07-08 安徽智飞龙科马生物制药有限公司 一种预防结核病的疫苗及联合用药物和制备方法、应用
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
CN118191298A (zh) * 2022-12-14 2024-06-14 上海索昕生物科技有限公司 一种抗体免疫检测试剂及其制备方法和应用
CN116286682B (zh) * 2022-12-30 2026-04-07 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
WO2025106425A1 (en) * 2023-11-13 2025-05-22 University Of Florida Research Foundation, Incorporated Immunogenic composition and uses thereof
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN119552230B (zh) * 2024-12-12 2026-03-13 中国人民解放军军事科学院军事医学研究院 一种脂肪酸化修饰的白喉毒素抗原及其应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
WO1997045444A1 (en) 1996-05-24 1997-12-04 The Council Of The Queensland Institute Of Medical Research Ebv ctl epitopes
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
WO1999002550A1 (en) 1997-07-10 1999-01-21 The Council Of The Queensland Institute Of Medical Research Ctl epitopes from ebv
WO2011098772A1 (en) 2010-02-11 2011-08-18 Isis Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
WO2015157820A1 (en) 2014-04-15 2015-10-22 Griffith University Group a streptococcus vaccine
WO2016172762A1 (en) 2015-04-25 2016-11-03 James Cook University Schistosomiasis vaccine
WO2016193746A1 (en) 2015-06-05 2016-12-08 Oxford University Innovation Limited Methods and products for fusion protein synthesis
WO2018017020A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
WO2018197854A1 (en) 2017-04-24 2018-11-01 Oxford University Innovation Limited Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
WO2019036761A1 (en) 2017-08-23 2019-02-28 Griffith University IMMUNOGENIC PEPTIDE DIRECTED AGAINST GROUP A STREPTOCOCCUS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
PL196114B1 (pl) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Ciałka inkluzyjne jako antygeny do doustnej immunizacji zwierząt
CN100999548B (zh) * 2006-01-10 2010-09-08 海南天源康泽医药科技有限公司 白喉毒素突变体crm197及其制备方法
CN102686238A (zh) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
KR20130072201A (ko) * 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
WO2015134402A1 (en) * 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli
EP3706787A4 (en) * 2017-11-06 2021-10-20 OZQ Pty Ltd VACCINE
US12053519B2 (en) * 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
WO1997045444A1 (en) 1996-05-24 1997-12-04 The Council Of The Queensland Institute Of Medical Research Ebv ctl epitopes
WO1999002550A1 (en) 1997-07-10 1999-01-21 The Council Of The Queensland Institute Of Medical Research Ctl epitopes from ebv
WO2011098772A1 (en) 2010-02-11 2011-08-18 Isis Innovation Limited Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
WO2015157820A1 (en) 2014-04-15 2015-10-22 Griffith University Group a streptococcus vaccine
WO2016172762A1 (en) 2015-04-25 2016-11-03 James Cook University Schistosomiasis vaccine
WO2016193746A1 (en) 2015-06-05 2016-12-08 Oxford University Innovation Limited Methods and products for fusion protein synthesis
WO2018017020A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines
WO2018197854A1 (en) 2017-04-24 2018-11-01 Oxford University Innovation Limited Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
WO2019036761A1 (en) 2017-08-23 2019-02-28 Griffith University IMMUNOGENIC PEPTIDE DIRECTED AGAINST GROUP A STREPTOCOCCUS
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用

Non-Patent Citations (85)

* Cited by examiner, † Cited by third party
Title
"CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1995, JOHN WILEY & SONS, INC.
"GenBank", Database accession no. AAV70486.1
"Remington's Pharmaceutical Sciences", 1991, MACK PUBLISHING CO.
ACKERMAN, A.L. ET AL.: "Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 100, no. 22, 2003, pages 12889 - 12894, XP002998292, DOI: 10.1073/pnas.1735556100
AH-REUM PARK ET AL: "Efficient recovery of recombinant CRM197 expressed as inclusion bodies in E.coli", PLOS ONE, vol. 13, no. 7, 18 July 2018 (2018-07-18), pages e0201060, XP055694392, DOI: 10.1371/journal.pone.0201060 *
ALTSCHUL ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389
ANDERSEN, P.K.B. URDAHL: "TB vaccines; promoting rapid and durable protection in the lung", CURRENT OPINION IN IMMUNOLOGY, vol. 35, 2015, pages 55 - 62
BAGHBAN ET AL., MOL BIOTECHNOL., vol. 61, no. 5, 2019, pages 365 - 384
BERNFIELD, M. ET AL.: "Functions of cell surface heparan sulfate proteoglycans", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 68, no. 1, 1999, pages 729 - 777, XP001032535, DOI: 10.1146/annurev.biochem.68.1.729
BHATT, K. ET AL.: "Quest for correlates of protection against tuberculosis", CLINICAL AND VACCINE IMMUNOLOGY, vol. 22, no. 3, 2015, pages 258 - 266
BILLESKOV, R. ET AL.: "The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity", PLOS ONE, vol. 7, no. 6, 2012
BROKER ET AL., BIOLOGICALS, vol. 39, 2011, pages 195
BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL ACAD. SET USA, vol. 94, 1997, pages 412 - 417
C. G. A THOMAS: "Medical Microbiology", 1983, BAILLIERE TINDALL
CHAN, J. ET AL.: "Seminars in immunology", 2014, ELSEVIER, article "The role ofB cells and humoral immunity in Mycobacterium tuberculosis infection"
CHEN, S. ET AL.: "Design of Bacterial Inclusion Bodies as Antigen Carrier Systems", ADVANCED BIOSYSTEMS, vol. 2, no. 11, 2018, pages 1800118
CHEN, S. ET AL.: "Innovative antigen carrier system for the development of tuberculosis vaccines", THE FASEB JOURNAL, 2019
CHEN, S. ET AL.: "New skin testfor detection of bovine tuberculosis on the basis of antigen-displaying polyester inclusions produced by recombinant Escherichia coli", APPL. ENVIRON. MICROBIOL., vol. 80, no. 8, 2014, pages 2526 - 2535, XP055216252, DOI: 10.1128/AEM.04168-13
COOPER, A.M.: "Cell-mediated immune responses in tuberculosis", ANNUAL REVIEW OF IMMUNOLOGY, vol. 27, 2009, pages 393 - 422
DAVID M. NEVILLE ET AL., ANN REV BIOCHEM., vol. 55, 1986, pages 195 - 224
DE TEMMERMAN, M.-L. ET AL.: "Particulate vaccines: on the quest for optimal delivery and immune response", DRUG DISCOVERY TODAY, vol. 16, no. 13-14, 2011, pages 569 - 582, XP028231719, DOI: 10.1016/j.drudis.2011.04.006
DIETRICH, J. ET AL.: "Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy", JOURNAL OF IMMUNOLOGY, vol. 174, no. 10, 2005, pages 6332 - 6339
DOE ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 2369 - 2376
ERICKSON ET AL., J. IMMUNOL., vol. 151, 1993, pages 4189 - 4199
FARKASBYSTRICKY, CHEMICAL PAPERS, vol. 64, no. 6, 2010, pages 683 - 695
FENTON, M.J. ET AL.: "Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 65, no. 12, 1997, pages 5149 - 5156
FERRER-MIRALLESVILLAVERDE, MICROB CELL FACT., vol. 12, 2013, pages 113
FOGED, C. ET AL.: "Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 298, no. 2, 2005, pages 315 - 322, XP004965888, DOI: 10.1016/j.ijpharm.2005.03.035
GELDENHUYS, H. ET AL.: "The tuberculosis vaccine H4:IC31 is safe and induces a persistentpolyfunctional CD4 T cell response in South African adults: A randomized controlled trial", VACCINE, vol. 33, no. 30, 2015, pages 3592 - 9, XP029214836, DOI: 10.1016/j.vaccine.2015.05.036
GIANNINI ET AL., NUCLEIC ACIDS RES., vol. 12, no. 10, 1984, pages 4063
GIANNINI ET AL., NUCLEIC ACIDS RES., vol. 12, no. 10, 25 May 1984 (1984-05-25), pages 4063 - 9
GIANNINI ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 4063
GONZALEZ-MIRO, M. ET AL.: "Polyester as antigen carrier toward particulate vaccines", BIOMACROMOLECULES, 2019
HATLEM ET AL., INT. J. MOL. SCI., vol. 20, 2019, pages 2129
HE, H.H. YANGY. DENG: "Mycobacterium tuberculosis dormancy-associated antigen of Rv2660c induces stronger immune response in latent Mycobacterium tuberculosis infection than that in active tuberculosis in a Chinese population", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, vol. 34, no. 6, 2015, pages 1103 - 1109
HOLMES, R., THE JOURNAL OF INFECTIOUS DISEASES, vol. 181, 2000, pages S 156 - S167
HONARY, S.F. ZAHIR: "Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 1", TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 12, no. 2, 2013, pages 255 - 264
HONARY, S.F. ZAHIR: "Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 2)", TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 12, no. 2, 2013, pages 265 - 273
HOUGHTON ET AL., HEPATOLOGY, vol. 14, 1991, pages 381 - 388
HU SHUN ET AL: "Conjugation of the CRM197-inulin conjugate significantly increases the immunogenicity ofMycobacterium tuberculosisCFP10-TB10.4 fusion protein", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, vol. 25, no. 21, 19 July 2017 (2017-07-19), pages 5968 - 5974, XP085244116, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2017.09.027 *
JAHNS, A.C. ET AL.: "In vivo self-assembly offluorescent protein microparticles displaying specific binding domains", BIOCONJUGATE CHEMISTRY, vol. 24, no. 8, 2013, pages 1314 - 1323, XP055550655, DOI: 10.1021/bc300551j
JASENOSKY, L.D. ET AL.: "T cells and adaptive immunity to Mycobacterium tuberculosis in humans", IMMUNOLOGICAL REVIEWS, vol. 264, no. 1, 2015, pages 74 - 87
KAUFMANN, S.H.E.: "Tuberculosis vaccines-a new kid on the block", NATURE MEDICINE, vol. 17, no. 2, 2011, pages 159 - 160
KHADER, S.A.R. GOPAL: "IL-17 in protective immunity to intracellular pathogens", VIRULENCE, vol. 1, no. 5, 2010, pages 423 - 427
KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884
LEWINSOHN, D.A.D.M. LEWINSOHNT.J. SCRIBA: "Polyfunctional CD4+ T cells as targets for tuberculosis vaccination", FRONTIERS IN IMMUNOLOGY, vol. 8, 2017, pages 1262
LIMBACH, L.K. ET AL.: "Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations", ENVIRONMENTAL SCIENCE & TECHNOLOGY, vol. 39, no. 23, 2005, pages 9370 - 9376
LIN, L.C.W. ET AL.: "Advances and Opportunities in Nanoparticle-and Nanomaterial-Based Vaccines against Bacterial Infections", ADVANCED HEALTHCARE MATERIALS, 2018, pages 1701395
LIN, P.L. ET AL.: "The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 1, 2012, pages 303 - 314
MAGGIOLI, M.F. ET AL.: "Polyfunctional cytokine production by central memory T cells from cattle in response to Mycobacterium bovis infection and BCG vaccination", AM ASSOC IMMNOL., 2016
MANNNDUNGU, VIROL J., vol. 12, 2015, pages 3
MARTINEZ-DONATO, G. ET AL.: "Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system", CLIN. VACCINE IMMUNOL., vol. 23, no. 4, 2016, pages 370 - 378
MAXWELL ET AL., MOL CELL BIOL., vol. 7, 1987, pages 1576
MIYAJI, E.N. ET AL.: "Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRMl9 7, a mutant diphtheria toxin", INFECTION AND IMMUNITY, vol. 69, no. 2, 2001, pages 869 - 874
MORELL, M. ET AL.: "Inclusion bodies: Specificity in their aggregation process and amyloid-like structure", BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, vol. 1783, no. 10, 2008, pages 1815 - 1825, XP026103653, DOI: 10.1016/j.bbamcr.2008.06.007
ORLANDO, V. ET AL.: "human cD4 T-cells With a naive Phenotype Produce Multiple cytokines During Mycobacterium Tuberculosis infection and correlate With active Disease", FRONTIERS IN IMMUNOLOGY, vol. 9, 2018
PAPPENHEIMER, A.M.D.M. GILL: "Diphtheria", SCIENCE, vol. 182, no. 4110, 1973, pages 353 - 358
PETERNEL, S. ET AL.: "Inclusion bodies contraction with implications in biotechnology", ACTA CHIMICA SLOVENICA, vol. 55, no. 3, 2008, pages 608 - 612
PETERNEL, S.R. KOMEL: "Active protein aggregates produced in Escherichia coli", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 12, no. 11, 2011, pages 8275 - 8287
PETERS, V.B.H.A. REHM: "In vivo monitoring of PHA granule formation using GFP-labeledPHA synthases", FERNS MICROBIOLOGY LETTERS, vol. 248, no. 1, 2005, pages 93 - 100
PROBST ET AL., J PHARM SCI., vol. 106, no. 8, 2017, pages 1952 - 1960
RAVI P.N. MISHRA ET AL: "Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines", BIOSCIENCE REPORTS, vol. 38, no. 5, 25 September 2018 (2018-09-25), XP055694493, ISSN: 0144-8463, DOI: 10.1042/BSR20180238 *
REDDINGTONHOWARTH, CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 29, 2015, pages 94 - 99
REHM, B.H.: "Bioengineering towards self-assembly of particulate vaccines", CURRENT OPINION IN BIOTECHNOLOGY, vol. 48, 2017, pages 42 - 53, XP085252978, DOI: 10.1016/j.copbio.2017.03.018
ROSENBERG, ANN. REV. MED., vol. 47, 1996, pages 481 - 491
RUAN ET AL., GENE, vol. 188, 1997, pages 35
RUBIO REYES, P. ET AL.: "Immunogencity of antigens from Mycobacterium tuberculosis self-assembled as particulate vaccines", INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY : IJMM, vol. 306, no. 8, 2016, pages 624 - 632
RUBIO-REYES, P. ET AL.: "Immunological properties and protective efficacy of a single mycobacterial antigen displayed on polyhydroxybutyrate beads", MICROBIAL BIOTECHNOLOGY, vol. 10, no. 6, 2017, pages 1434 - 1440
SAHIN ET AL., CUM OPIN. IMMUNOL., vol. 9, 1997, pages 709 - 716
SAMBROOK ET AL.: "MOLECULAR CLONING, A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS
SHAFIKHANI ET AL., BIOTECHNIQUES, vol. 23, 1997, pages 304
SHUXIONG CHEN ET AL: "Design of Bacterial Inclusion Bodies as Antigen Carrier Systems", ADVANCED BIOSYSTEMS, vol. 2, no. 11, 4 September 2018 (2018-09-04), pages 1800118, XP055694372, ISSN: 2366-7478, DOI: 10.1002/adbi.201800118 *
SINGH ET AL., MICROB CELL FACT., vol. 14, 2015, pages 41
SPICERDAVIS, NATURE COMMUNICATIONS, vol. 5, 2014, pages 4740
STEMMER, PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 10747
TORRADO, E.A.M. COOPER: "IL-17 and Thl7 cells in tuberculosis", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 21, no. 6, 2010, pages 455 - 462, XP027543808
TRUC, H. ET AL.: "ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre-and post-exposure tuberculosis vaccination", PLOS ONE, vol. 8, no. 12, 2013, XP055098506, DOI: 10.1371/journal.pone.0080579
UCHIDA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 248, 1973, pages 3845 - 3850
VAN DEN EYNDEVAN DER BRUGGEN, CURR. OPIN. IMMUNOL., vol. 9, 1997, pages 684 - 693
VEGGIANI ET AL., TRENDS BIOTECHNOL., vol. 32, no. 10, October 2014 (2014-10-01), pages 506 - 12
WOODARD, R.W.T.C. MEREDITHP. AGGARWAL: "Viable non-toxic gram-negative bacteria", GOOGLE PATENTS, 2012
ZACCOFO ET AL., J. MOL. BIOL., vol. 255, 1996, pages 589
ZHANG H L ET AL: "A novel combined conjugate vaccine: Enhanced immunogenicity of bFGF with CRM197 as a carrier protein", MOLECULAR MEDICINE REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 4, no. 5, 1 September 2011 (2011-09-01), pages 857 - 863, XP002686440, ISSN: 1791-2997, [retrieved on 20110629], DOI: 10.3892/MMR.2011.521 *
ZHOU ET AL., MICROB CELL FACT., vol. 11, 2012, pages 10

Also Published As

Publication number Publication date
EP4031170A4 (en) 2023-11-15
US20220378894A1 (en) 2022-12-01
AU2020349589A1 (en) 2022-04-07
WO2021051153A9 (en) 2022-12-29
CN115175696A (zh) 2022-10-11
WO2021051153A1 (en) 2021-03-25
EP4031170A1 (en) 2022-07-27
JP2022549791A (ja) 2022-11-29

Similar Documents

Publication Publication Date Title
NL2023863B1 (en) Protein particles and uses thereof
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
JP5933437B2 (ja) T細胞ヘルプを誘発する組成物
AU2019315602B2 (en) Nipah virus immunogens and their use
CN105307673A (zh) 用于稳健的体液及细胞免疫应答的亚单位疫苗递送平台
EP2953638A1 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
US11078491B2 (en) Vaccines against Zika virus based on Zika structure proteins
AU2015292261B2 (en) Constrained proteins and uses therefor
US10301362B2 (en) Group A Streptococcus vaccine
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
JP2012510289A (ja) グルタミルtRNA合成酵素(GtS)フラグメント
RS53769B1 (sr) Imunogena jedinjenja koja sadrže hiv gp41 peptid spojen na crm197 belančevinu-nosioc
EP2742139A1 (en) Immunogenic compositions and methods therefor
US11732033B2 (en) Immunogenic peptide against group a Streptococcus
HK40081102A (en) Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
US12440557B2 (en) Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
JP2022546465A (ja) ワクチン有効性の増加方法

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20221001